AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|AAPL294.38+5.02 (+1.73%) ▲|ABBV251.06-0.58 (-0.23%) ▼|ABT92.18+1.44 (+1.59%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE210.98+5.96 (+2.91%) ▲|AMAT650.91-72.09 (-9.97%) ▼|AMD540.88-40.03 (-6.89%) ▼|AMGN361.33-0.79 (-0.22%) ▼|AMT166.08+2.51 (+1.53%) ▲|AMZN241.70+3.36 (+1.41%) ▲|AVGO369.34-8.41 (-2.23%) ▼|AXP348.00+9.75 (+2.88%) ▲|BA218.58+2.11 (+0.97%) ▲|BAC58.36+1.38 (+2.42%) ▲|BKNG182.64+4.40 (+2.47%) ▲|BLK980.38+18.82 (+1.96%) ▲|BMY56.44-1.18 (-2.05%) ▼|BNY146.02+1.41 (+0.98%) ▲|BRK-B499.74-0.65 (-0.13%) ▼|C140.13+0.17 (+0.12%) ▲|CAT991.41-73.49 (-6.90%) ▼|CL92.76+1.08 (+1.18%) ▲|CMCSA23.73-0.82 (-3.34%) ▼|COF204.82+4.20 (+2.09%) ▲|COP103.22-0.74 (-0.71%) ▼|COST924.67-10.80 (-1.15%) ▼|CRM163.23+6.57 (+4.19%) ▲|CSCO117.01-0.45 (-0.38%) ▼|CVS104.81+1.36 (+1.31%) ▲|CVX165.69-0.07 (-0.04%) ▼|DE627.63-6.70 (-1.06%) ▼|DHR193.72+3.24 (+1.70%) ▲|DIS95.71-0.54 (-0.56%) ▼|DUK125.77-0.81 (-0.64%) ▼|EMR139.52-3.63 (-2.54%) ▼|FDX313.89+0.76 (+0.24%) ▲|GD362.86+8.62 (+2.43%) ▲|GE374.94+1.21 (+0.32%) ▲|GEV1,134.35-40.51 (-3.45%) ▼|GILD125.97-0.37 (-0.29%) ▼|GM75.52-1.56 (-2.02%) ▼|GOOG357.89+4.56 (+1.29%) ▲|GOOGL361.21+3.84 (+1.07%) ▲|GS1,019.61+8.24 (+0.81%) ▲|HD350.84-1.84 (-0.52%) ▼|HON221.75-2.15 (-0.96%) ▼|IBM286.25+5.04 (+1.79%) ▲|INTC127.02-12.61 (-9.03%) ▼|INTU267.08+6.08 (+2.33%) ▲|ISRG402.38+4.70 (+1.18%) ▲|JNJ253.98+0.01 (+0.00%) ▲|JPM334.07+6.74 (+2.06%) ▲|KO81.29+0.02 (+0.02%) ▲|LIN533.55+14.61 (+2.82%) ▲|LLY1,191.74-7.69 (-0.64%) ▼|LMT521.82+12.36 (+2.43%) ▲|LOW221.92+1.43 (+0.65%) ▲|LRCX391.26-42.07 (-9.71%) ▼|MA522.44+8.84 (+1.72%) ▲|MCD269.43-0.88 (-0.33%) ▼|MDLZ59.35+1.51 (+2.61%) ▲|MDT79.20+0.97 (+1.24%) ▲|META612.91+49.62 (+8.81%) ▲|MMM159.96-1.95 (-1.20%) ▼|MO71.54-0.41 (-0.57%) ▼|MRK125.37-3.13 (-2.44%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT384.28+11.26 (+3.02%) ▲|MU1,032.28-122.01 (-10.57%) ▼|NEE86.37-1.40 (-1.60%) ▼|NFLX74.19+2.79 (+3.91%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.80+6.52 (+6.57%) ▲|NVDA197.58-2.51 (-1.25%) ▼|ORCL142.50-4.05 (-2.76%) ▼|PEP141.16+5.76 (+4.25%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.43+0.79 (+0.54%) ▲|PLTR125.73+9.06 (+7.77%) ▲|PM177.69-3.22 (-1.78%) ▼|QCOM181.92-2.87 (-1.55%) ▼|RTX191.78+2.05 (+1.08%) ▲|SBUX103.39+1.20 (+1.17%) ▲|SCHW95.78+3.51 (+3.80%) ▲|SO95.12-0.59 (-0.62%) ▼|SPG223.00-0.65 (-0.29%) ▼|T20.48-0.22 (-1.06%) ▼|TMO513.33+11.97 (+2.39%) ▲|TMUS173.06+5.33 (+3.18%) ▲|TSLA425.30+4.70 (+1.12%) ▲|TXN298.41+0.34 (+0.11%) ▲|UBER72.66+0.50 (+0.69%) ▲|UNH426.54+10.91 (+2.62%) ▲|UNP277.73+5.73 (+2.11%) ▲|UPS109.54+2.04 (+1.90%) ▲|USB61.96+1.56 (+2.58%) ▲|V351.08+7.99 (+2.33%) ▲|VZ41.99-0.35 (-0.83%) ▼|WFC85.94+3.30 (+3.99%) ▲|WMT108.82-4.44 (-3.92%) ▼|XOM136.28-0.44 (-0.32%) ▼|
28.8 C
New York
Thursday, July 2, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery

KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its highly anticipated fourth edition...

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of...

SDP Japan Raises $31 Million in Series D Round

Pioneering the Future of Surgical Care in Response to Rising DemandTOKYO, June 15, 2025 /PRNewswire/ -- SDP Japan, Inc. (Shibuya-ku, Tokyo; CEO: Kazuhiko Nagayo),...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Statement from the Alzheimer’s Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ --...

Over 2000 Canadians take a big step for breakthroughs in cancer research and raise over $1.75 Million in support of The Princess Margaret

Participants of all ages come together to create a world free from the fear of cancer TORONTO, June 15, 2025 /CNW/ - Participants of all...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Redtiger Celebrates 5 Years of Bestselling Dash Cams for Cars With Discounts, Giveaways, and More

Marking five years of empowering drivers and vehicle owners to keep themselves and their passengers safe on the road, Redtiger is celebrating the anniversary with...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers